Company news

Amneal Pharmaceuticals, Inc. news in 2025

Amneal Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

December 21, 2025

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

December 8, 2025

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

December 4, 2025

Amneal to Participate in Upcoming Investor Conferences

December 2, 2025

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

December 1, 2025

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

November 30, 2025

Amneal Receives U.S. FDA Approval for Iohexol Injection

November 12, 2025

Amneal Reports Third Quarter 2025 Financial Results

October 29, 2025

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

October 28, 2025

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

October 26, 2025

Amneal to Report Third Quarter 2025 Results on October 30, 2025

September 30, 2025

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

September 25, 2025

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

September 22, 2025

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

September 10, 2025

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

September 3, 2025

Amneal Reports Second Quarter 2025 Financial Results

August 4, 2025

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

July 20, 2025

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

July 20, 2025

Amneal to Report Second Quarter 2025 Results on August 5, 2025

July 9, 2025

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

June 25, 2025

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

June 11, 2025

Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

May 14, 2025

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

May 8, 2025

Amneal Reports First Quarter 2025 Financial Results

May 1, 2025

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

April 10, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

April 6, 2025

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

April 2, 2025

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

March 31, 2025

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

March 2, 2025

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

February 18, 2025

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

January 22, 2025

Calls in 2025

Decks in 2025